Lyudmila Bazhenova, MD

Articles by Lyudmila Bazhenova, MD

Lung Cancer Experts Detail Challenges of Cisplatin/Carboplatin Shortages

ByEdward S. Kim, MD, MBA,Heather Wakelee, MD,Karen L. Reckamp, MD, MS,Edgardo S. Santos Castillero, MD, FACP, FASCO,Lyudmila Bazhenova, MD

September 13th 2023

Experts discuss the challenges of the ongoing cisplatin and carboplatin shortages in the United States and detail how they are adapting in their practices.

Dr. Bazhenova on the Potential Approval of Lorlatinib for Patients With ALK-Positive NSCLC

ByLyudmila Bazhenova, MD

May 7th 2018

Lyudmila Bazhenova, MD, professor of clinical medicine, University of California, San Diego, discusses the potential approval of lorlatinib for patients with ALK-positive non–small cell lung cancer (NSCLC).

Latest Updated Articles

Dr. Bazhenova on the Potential Approval of Lorlatinib for Patients With ALK-Positive NSCLC
Published: May 7th 2018 | Updated:

Lyudmila Bazhenova, MD

Articles by Lyudmila Bazhenova, MD

Lung Cancer Experts Detail Challenges of Cisplatin/Carboplatin Shortages

Dr. Bazhenova on the Potential Approval of Lorlatinib for Patients With ALK-Positive NSCLC

Latest Updated Articles

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma

Dr Bardia on the Efficacy of Giredestrant in ER+, HER2-Negative Early Breast Cancer